Drug-Induced Thrombocytopenia Severity and Toxicity (DITPst): binary classification of drugs by human thrombocytopenia toxicity.

Abstract

Background: Drug-induced thrombocytopenia (DITP) often occurs in patients during clinical treatment. However, clinicians usually fail to distinguish which drugs can be plausible culprits accurately. We aimed to develop a large comprehensive drug benchmark database with DITP toxicity using the recommended method by FDA.

Research design and methods: We collected information from six databases that involved drug labeling information, literature, safety signal mining and laboratory testing to generate the annotated drug list with DITP toxicity. Then, we descripted the DITP positive-negative distribution based on the Anatomical Therapeutic Chemical (ATC) coding system; hotspot analysis was conducted to identify therapeutic categories of drugs within each organ system that warrant attention regarding DITP.

Results: The DITPst database comprised 1,765 drugs, of which 858 were DITP-positives, whereas 907 were negatives. The investigation of distribution across various therapeutic categories revealed the most frequent DITP-positive categories were immunostimulants (10/11), anti-inflammatory, and antirheumatic products (28/32), and antibacterials for systemic use (102/121). On the contrary, the least frequent DITP-positive therapeutic categories were diagnostic radiopharmaceuticals (12/12), pituitary and hypothalamic hormones and analogues (17/18), and drugs for constipation (16/17).

Conclusions: We consider the DITPst benchmark database to be an invaluable resource for the community to improve DITP safety research and drug development.